[1]戴 璐.柳氮磺胺吡啶联合益赛普治疗不同年龄强直性脊柱炎 临床效果及对患者生活质量的影响研究*[J].陕西医学杂志,2019,(2):262-265.
　DAI Lu..Clinical effect of sulfasalazine combined with Yisaipu on ankylosing spondylitis in different age groups and its impact on patients’ quality of life[J].,2019,(2):262-265.
点击复制

柳氮磺胺吡啶联合益赛普治疗不同年龄强直性脊柱炎 临床效果及对患者生活质量的影响研究*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2019年2期
页码:
262-265
栏目:
药物与临床
出版日期:
2020-02-05

文章信息/Info

Title:
Clinical effect of sulfasalazine combined with Yisaipu on ankylosing  spondylitis in different age groups and its impact on patients’ quality of life
文章编号:
DOI: 10.3969/j.issn.10007377.2019.02.034
作者:
戴 璐
西安市第五医院骨质疏松科（西安710082）
Author(s):
DAI Lu.
Department of Osteoporosis, Xi’an No.5 Hospital(Xi’an 710082)
关键词:
强直性脊柱炎; 药物疗法; 老年人; 成年人; 对比研究; 生活质量
Keywords:
Key words Ankylosing spondylitis; Drug therapy; Aged; Adult; Comparative study; Quality of life
分类号:
R593.23
文献标志码:
A
摘要:
摘 要 目的：探讨柳氮磺胺吡啶联合益赛普治疗不同年龄群体强直性脊柱炎（AS）的临床效果及对患者生活质量的影响。方法：选择分层随机抽签方式从AS患者中抽选年龄25～40岁（壮年组）和60～75岁（老年组）患者进行研究。两组均接受柳氮磺胺吡啶联合益赛普进行治疗，持续用药，待病情缓解后将两组益赛普剂量减半。记录了两组益赛普剂量减半时间及剂量减半后病情反复者人数；记录两组治疗1、2、4、6个月达到ASAS20改善者人数；治疗前后分别评估两组关节活动情况及生活质量；观察两组不良反应情况。结果：与老年组比，壮年组益赛普剂量减半时间明显缩短，减半后病情反弹人数明显减少（P＜0.05）。治疗第1个月，两组达到ASAS20改善人数间差异无统计学意义（P＞0.05）；第2个月，壮年组达标人数明显多于老年组（P＜0.05）；第4、6个月壮年组达到ASAS20改善人数与2第个月间差异无统计学意义（P＞0.05）；但老年组第6个月达标人数明显少于第2个月（P＜0.05）。治疗前，壮年组Schober试验、扩胸度、颈部旋度及腰部侧弯距离均明显大于老年组（P＜0.05）。治疗后，壮年组和老年组4项关节功能指标均明显增大，且壮年组治疗前后差值均明显大于老年组（P＜0.05）。壮年组治疗前总体健康评分明显高于老年组（P＜0.05）。治疗后，两组生理职能、生理机能、躯体疼痛、生活活力、社会功能、情感职能及总体健康评分较治疗前均明显提高，且壮年组治疗前后各维度差值均明显高于老年组（P＜0.05）。结论：老年AS患者关节功能受限程度更严重，总体健康程度低。老年或壮年AS均可采用柳氮磺胺吡啶和益赛普进行治疗，经治疗患者关节活动度及生活质量均得到明显改善。但相对而言，壮年患者改善更明显，因此要做好AS的早期预防及治疗。 
Abstract:
Abstract Objective：To investigate the clinical effects of sulfasalazine combined with Yisaipu on ankylosing spondylitis (AS) in different age groups and its impact on patients' quality of life.Methods：Patients with ages of 25～40 years (adult group) and 60～75 years old (elderly group) were selected from AS patients by stratified random sampling.Patients of both groups were treated with sulfasalazine in combination with Yisaipu for continuous, and the dose of Yisaipu was halved after the condition was relieved.The time between the two groups of Yisaipu dose was halved, and the number of patients with AS repeated was recorded. Record the number of people who achieved ASAS20 improvement in 1, 2, 4, and 6 months of treatment.The activity and quality of life of the two groups before and after treatment were evaluated. The adverse reactions of the two groups were observed.Results：Compared with the elderly group, the dose reduction time of the Yisaipu group in the adult group was significantly shortened, and the number of rebounded patients was significantly reduced after halving (P<0.05).At the first month of treatment, there was no significant difference in the number of ASAS20 improvement between the two groups (P>0.05).In the second month, the number of people in the adult group was significantly higher than that in the elderly group (P<0.05).There was no significant difference in the number of ASAS20 improvement between the fourth and sixth months of the adult group and the second month (P>0.05).However, the number of people who met the〖LM〗 standard in the 6th month was significantly less than that in the second month (P<0.05).Before treatment, the Schober test, chest expansion, neck rotation and lumbar scoliosis distance in the adult group were significantly greater than those in the elderly group (P<0.05).After treatment, the four joint function indexes of the adult group and the elderly group were significantly increased, and the difference before and after treatment in the adult group was significantly greater than that of the elderly group (P<0.05).The overall health score of the adult group before treatment was significantly higher than that of the elderly group (P<0.05).After treatment, the physiological functions, physiological functions, physical pain, vitality, social function, emotional function and overall health score of the two groups were significantly improved compared with those before treatment, and the differences of the dimensions in the adult group before and after treatment were significantly higher than those of the elderly group (P<0.05).Conclusion：In elderly patients with AS, the degree of joint function is more severe and the overall health is low.Old or advanced AS can be treated with sulfasalazine and Yisaipu, and the joint mobility and quality of life of the treated patients are significantly improved.However, relatively speaking, the improvement of patients in the adult of life is more obvious, so it is better to prevent and treat AS early.

参考文献/References:

\[1\] 〖JP3〗郑红霞, 章伟明, 王 圳,等. 雷公藤多苷、白芍总苷联合柳氮磺胺吡啶诱导缓解并维持性治疗强直性脊柱炎的临床观察\[J\]. 中国中西医结合杂志, 2018, 38(6)：651654.〖JP〗
\[2\] 张兰玲, 张 菊, 庞亚飞,等. 重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白联合柳氮磺吡啶诱导缓解并维持治疗活动性强直性脊柱炎的临床研究\[J\]. 中华风湿病学杂志, 2014, 18(2)：110113.
\[3\] 庞琳烜, 杨西超, 郑朝晖,等. 重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白与免疫抑制剂治疗强直性脊柱炎临床观察\[J\]. 解放军医药杂志, 2016, 28(7)：9295.
\[4\] 龚家川. 评价强直性脊柱炎病情活动度评分对强直性脊柱炎患者病情活动性判断价值\[J\]. 中国实用医药,2016,11(5)：7273.
\[5\] 王 岩,张雪芳,李 杰,等. 强直性脊柱炎伴缺血性脑血管事件患者的危险因素分析\[J\]. 中华老年心脑血管病杂志,2015,17(5)：472474.
\[6\] 汪年松, 薛 勤. 强直性脊柱炎\[M\]. 2 版. 北京：人民卫生出版社, 2010：196199.
\[7\] 徐荣敏,陈国军,洪明飞. 六味地黄丸对老年肝肾阴虚型强直性脊柱炎患者临床疗效的影响\[J\]. 中国老年学杂志,2016,36(22):56955696.
\[8\] 程随涛. 强直性脊柱炎伴发葡萄膜炎20例临床特征分析\[J\]. 陕西医学杂志, 2016, 45(10):13821383.
\[9\] 张 莉, 沈海丽. 老年强直性脊柱炎患者临床治疗及生活质量现况分析\[J\]. 中国地方病防治杂志, 2018, 33(2):177178.〖ZK)〗
\[10\] 侯东杰, 王建民. 益赛普与柳氮磺胺吡啶治疗强直性脊柱炎的Mete分析\[J\]. 宁夏医科大学学报, 2014, 36(5):545552.
\[11\] 孙素和,王鹏,苏春燕,等. 强直性脊柱炎患者骨髓间充质干细胞调控巨噬细胞的功能异常\[J\]. 中国组织工程研究,2016,20(1):1319.
\[12\] 雷 静,刘志豪,贾 琼. 四妙丸加味联合英夫利昔单抗治疗强直性脊柱炎30例临床观察\[J\]. 中医药导报,2015,21(15):7476.
\[13\] 〖JP3〗Genre F, LópezMejías R, MirandaFilloy J A,et al. Osteoprotegerin correlates with disease activity and endothelial activation in nondiabetic ankylosing spondylitis patients undergoing TNFα antagonist therapy\[J\]. Clinical & Experimental Rheumatology, 2014, 32(5):640646.〖JP〗〖ZK)〗

相似文献/References:

[1]张家豪,孙超峰.伊伐布雷定治疗冠心病合并慢性阻塞性肺病心力衰竭临床疗效研究[J].陕西医学杂志,2019,(2):256.
　ZHANG Jiahao,SUN Chaofeng..Clinical effect of Ivabradine on Coronary heart disease combined with chronic obstructive pulmonary disease.[J].,2019,(2):256.
[2]郭 萍,王丽君.莫沙必利与双歧杆菌分别联合聚乙二醇散治疗功能性便秘的疗效及安全性分析*[J].陕西医学杂志,2019,(4):508.
　GUO Ping,WANG Lijun..Efficacy and safety of mosapride and bifidobacteria combined with polyethylene glycol powder in the treatment of functional constipation[J].,2019,(2):508.
[3]李 涛,李界兴△,尚同军,等.奥氮平片与利培酮片治疗男性精神分裂症疗效、安全性及对患者生活质量影响对比研究[J].陕西医学杂志,2019,(5):657.
　LI Tao,LI Jiexing,SHANG Tongjun,et al.A comparative study on the efficacy, safety and impact of olanzapine tablets and risperidone tablets on male patients with schizophrenia[J].,2019,(2):657.
[4]沈 健,张雨涵,曹芳蕾,等.强直性脊柱炎患者血清RANKL、TGF-β1和TGF-β2的表达及临床意义[J].陕西医学杂志,2019,(8):981.
　SHEN Jian,ZHANG Yuhan,CAO Fanglei,et al.Clinical significance of RANKL, TGF-β1 and TGF-β2 in ankylosing spondylitis[J].,2019,(2):981.
[5]乔谷媛,陈必良,谭明华,等.妊娠合并白血病22例临床分析*[J].陕西医学杂志,2019,(9):1141.
[6]马明铭,李 芳,杨 慧,等.丙种球蛋白联合加倍剂量甲泼尼龙治疗常规剂量甲泼尼龙无效〖JZ〗难治性支原体肺炎疗效观察[J].陕西医学杂志,2019,(10):1374.
　MA Mingming,LI Fang,YANG Hui,et al.Therapeutic effect of gamma globulin combined with double dose of methylprednisolone on 〖JZ〗refractory mycoplasmal pneumonia with conventional dose of methylprednisolone[J].,2019,(2):1374.
[7]沈斯瑶,刘 艳△,徐鹏刚.白芍总苷联合沙利度胺治疗强直性脊柱炎疗效及对患者活动指标、血清炎性因子水平的影响*[J].陕西医学杂志,2020,49(1):20.
　SHEN Siyao,LIU Yan,XU Penggang..Effect of total glucosides of paeony combined with thalidomide on activity indicators and serum inflammatory factors in the treatment of ankylosing spondylitis patients[J].,2020,49(2):20.
[8]牛 敏,杨西超,闫美茜,等.强直性脊柱炎患者肥胖与炎性指标、疾病严重程度指标和心血管疾患危险因素指标相关性分析[J].陕西医学杂志,2021,50(11):1383.[doi:DOI:10.3969/j.issn.1000-7377.2021.11.015]
　NIU Min,YANG Xichao,YAN Meixi,et al.Correlation between obesity and inflammatory indicators,disease severity indicators and cardiovascular disease risk factors in patients with ankylosing spondylitis[J].,2021,50(2):1383.[doi:DOI:10.3969/j.issn.1000-7377.2021.11.015]

备注/Memo

备注/Memo:
*陕西省自然科学基础研究计划项目(2009JM4032)
更新日期/Last Update: 2019-03-13